Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to $4.0 million.

  • InMed Pharmaceuticals' Shares Outstanding (Diluted Average) rose 537.70% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 537.70%. This contributed to the annual value of $975,985 for FY2025, which is 156.13% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $4.0 million for Q3 2025, which was up 305.19% from $975,985 recorded in Q2 2025.
  • InMed Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $4.0 million during Q3 2025, with a 5-year trough of $166,410 in Q3 2023.
  • In the last 3 years, InMed Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $663,336 in 2024 and averaged $1.1 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Shares Outstanding (Diluted Average) plummeted by 84.44% in 2024, and later surged by 537.70% in 2025.
  • Quarterly analysis of 4 years shows InMed Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $566,062 in 2022, then reached $398,673 in 2023, then skyrocketed by 77.22% to $706,546 in 2024, then soared by 537.70% to $4.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $4.0 million for Q3 2025, versus $975,985 for Q2 2025 and $1.1 million for Q1 2025.